Register here to attend the event online
Essential healthcare products, such as vaccines and medicines, remain unaffordable and unavailable in much of the world, particularly impacting the 83% of the world’s population living in low-and middle-income countries (LMICs). Innovative pharmaceutical companies play a key role in improving the situation for billions across the world. For more than 15 years, the Access to Medicine Foundation has been assessing and tracking the industry’s actions to improve access to medicine in LMICs.
The Access to Medicine Index, published regularly since 2008 and now in its 8th edition, tracks progress, identifies best practices and demonstrates where action is urgently needed to improve access to medicine for some of the world’s most vulnerable populations. Due to be released on 15 November 2022, the latest edition of the Index will take a fresh look at how the world’s largest innovative pharmaceutical companies are performing on access to medicine.
Chatham House in partnership with the Access to Medicine Foundation will host an expert panel event to review the 2022 Access to Medicine Index’s key findings and identify how lessons learned from the COVID-19 pandemic can be applied to other specific health areas.
Through facilitated discussions on best practices and solutions, participants from various sectors will identify key priorities and what actions need to be taken to increase equitable access to critical health products in other disease areas, with an emphasis on vulnerable populations.
Topics for discussion will include:
What are the key findings from the 2022 Access to Medicine Index?
How has the COVID-19 pandemic shifted thinking around global health equity and the importance of improving access to medicine?
What are the most important lessons learned from innovative pharmaceutical companies during the COVID-19 pandemic?
How can pharmaceutical companies apply these key lessons to other disease areas?
How can global health funders support the development of more sustainable approaches to the development and delivery of products to support the most vulnerable populations in LMICs?
Where is progress needed the most?
How can pharmaceutical companies be further incentivised to fill the gaps in access?